|
1.
|
|
18 p, 2.5 MB |
The EHA Research Roadmap : Malignant Lymphoid Diseases
/
Dreyling, Martin (LMU Hospital (Alemanya)) ;
André, Marc (Université Catholique de Louvain (bèlgica)) ;
Gökbuget, Nicola (Goethe University (Alemanya)) ;
Tilly, Hervé (Centre Henri Becquerel and Université de Rouen (França)) ;
Jerkeman, Mats (Skåne University and Lund University (Suècia)) ;
Gribben, John (Queen Mary University of London (Regne Unit)) ;
Ferreri, Andrés (IRCCS San Raffaele Scientific Institute (Itàlia)) ;
Morel, Pierre (CHU Amiens Picardie (França)) ;
Stilgenbauer, Stephan (Universität Ulm (Alemanya)) ;
Fox, Christopher (University of Nottingham (Regne Unit)) ;
Maria Ribera, José (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Zweegman, Sonja (Amsterdam UMC (Països Baixos)) ;
Aurer, Igor (University of Zagreb (Zagreb)) ;
Bödör, Csaba (Semmelweis University (Hongria)) ;
Burkhardt, Birgit (Pädiatrische Hämatologie und Onkologie (Alemanya)) ;
Buske, Christian (University Hospital of Ulm (Alemanya)) ;
Dollores Caballero, Maria (El Instituto de Investigación Biomédica de Salamanca (Salamanca, Espanya)) ;
Campo, Elias (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Chapuy, Bjoern (Berlin Institute of Health (Alemanya)) ;
Davies, Andrew (University of Southampton (Regne Unit)) ;
de Leval, Laurence (Lausanne University Switzerland (Suïssa)) ;
Doorduijn, Jeanette (University Medical Center Rotterdam the Netherlands (Països Baixos)) ;
Federico, Massimo (GVM Care & Research (Itàlia)) ;
Gaulard, Philippe (Hôpital Henri Mondor (França)) ;
Gay, Francesca (AOU Città Della Salute e Della Scienza (Itàlia)) ;
Ghia, Paolo (IRCCS Ospedale San Raffaele (Itàlia)) ;
Grønbæk, Kirsten (University of Copenhagen (Dinamarca)) ;
Goldschmidt, Hartmut (University Hospital Heidelberg (Alemanya)) ;
Kersten, Marie-Jose (Cancer Center Amsterdam and LYMMCARE the Netherlands (Països Baixos)) ;
Kiesewetter, Barbara (Medical University of Vienna (Àustria)) ;
Landman-Parker, Judith (Sorbonne Université APHP/hôpital A Trousseau (França)) ;
Le Gouill, Steven (Clinique du Centre Hospitalier Universitaire (CHU) de Nantes (França)) ;
Lenz, Georg (Medical University Hospital Münster (Alemanya)) ;
Leppä, Sirpa (Helsinki University Hospital Comprehensive Cancer Centre Finland (Finlandia)) ;
López Guillermo, Armando (Hospital Clínic i Provincial de Barcelona) ;
Macintyre, Elizabeth (Assistance Publique-Hôpitaux de Paris (França)) ;
Mantega, Maria Victoria Mateos (Universidad de Salamanca (Salamanca, Espanya)) ;
Moreau, Philippe (University Hospital Hotel-Dieu (França)) ;
Moreno, Carol (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Nadel, Bertrand (Aix Marseille Univ (França)) ;
Okosun, Jessica (Queen Mary University of London (Regne Unit)) ;
Owen, Roger (St James's Institute of Oncology (Regne Unit)) ;
Pospisilova, Sarka (University Hospital Brno (Txèquia)) ;
Pott, Christiane (Universitätsklinikum Schleswig-Holstein (Alemanya)) ;
Robak, Tadeusz (Medical University of Lodz (Polònia)) ;
Spina, Michelle (National Cancer Institute (Itàlia)) ;
Stamatopoulos, Kostas (Centre for Research and Technology Hellas Greece (Grècia)) ;
Stary, Jan (Charles University Prague University Hospital Czech Republic (Txèquia)) ;
Tarte, Karin (Immunology and Cell Therapy Lab at Rennes University Hospital (França)) ;
Tedeschi, Allessandra (Niguarda Hospital Milano (Itàlia)) ;
Thieblemont, Catherine (Assistance Publique-Hôpitaux de Paris (França)) ;
Trappe, Ralf Ulrich (DIAKO Hospital Bremen (Alemanya)) ;
Trümper, Lorenz H. (University Medicine Goettingen (Alemanya)) ;
Salles, Gilles (Weill Cornell Medicine (Estats Units)) ;
Universitat Autònoma de Barcelona
2022 -  10.1097/HS9.0000000000000726
HemaSphere, Vol. 6 (may 2022)
|
|
|
2.
|
|
7 p, 820.3 KB |
Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
/
Stein, A. S. (Gehr Family Center for Leukemia Research. City of Hope) ;
Kantarjian, H. (The University of Texas M.D. Anderson Cancer Center) ;
Gökbuget, N. (Department of Medicine II. Goethe University) ;
Bargou, R. C. (Comprehensive Cancer Center Mainfranken. University Hospital Würzburg) ;
Litzow, Mark R (Mayo Clinic) ;
Rambaldi, Alessandro (Department of Oncology and Hemato-Oncology. University of Milan and Azienda Pope John XXIII Hospital) ;
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Zhang, A. (Amgen Inc.) ;
Zimmerman, Z. (Amgen Inc.) ;
Zugmaier, Gerhard (Amgen Research Munich) ;
Topp, M. S. (Medical Clinic and Polyclinic II. University Hospital Würzburg) ;
Universitat Autònoma de Barcelona
Patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) following allogeneic hematopoietic stem cell transplantation (alloHSCT) have a poor prognosis, and alternative therapies are needed for this patient population. [...]
2019 - 10.1016/j.bbmt.2019.04.010
Biology of blood and marrow transplantation, Vol. 25 Núm. 8 (august 2019) , p. 1498-1504
|
|
|
3.
|
|
6 p, 186.9 KB |
Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab
/
Topp, Max S. (Universitätsklinikum Würzburg) ;
Gökbuget, Nicola (Goethe University) ;
Zugmaier, Gerhard (Amgen GmbH) ;
Stein, Anthony S. (Gehr Family Center for Leukemia Research. City of Hope) ;
Dombret, Hervé (Saint Louis Hospital. University of Paris) ;
Chen, Yuqi (Amgen. Inc) ;
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bargou, Ralf C. (Comprehensive Cancer Center Mainfranken. University Hospital Würzburg) ;
Horst, Heinz-August (Universitätsklinikum Schleswig-Holstein (Alemanya)) ;
Kantarjian, H. M. (The University of Texas MD Anderson Cancer Center) ;
Universitat Autònoma de Barcelona
Background: Blinatumomab is a CD19 BiTE (bispecific T-cell engager) immuno-oncology therapy that mediates the lysis of cells expressing CD19. Methods: A pooled analysis of long-term follow-up data from 2 phase 2 studies that evaluated blinatumomab in heavily pretreated adults with Philadelphia chromosome-negative, relapsed/refractory B-cell precursor acute lymphoblastic leukemia was conducted. [...]
2021 - 10.1002/cncr.33298
Cancer, Vol. 127 Núm. 4 (15 2021) , p. 554-559
|
|
|
4.
|
|
18 p, 451.1 KB |
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
/
Kiesewetter, B. (Department of Medicine i. Clinical Division of Oncology. Medical University of Vienna) ;
Cherny, N. I. (Cancer Pain and Palliative Medicine Service. Department of Medical Oncology. Shaare Zedek Medical Center) ;
Boissel, Nicolas (Diderot University Paris Faculty of Medicine) ;
Cerisoli, F. (European Hematology Association) ;
Dafni, U. (Frontier Science Foundation-Hellas) ;
De Vries, Elisabeth G. E. (Department of Medical Oncology. University Medical Center Groningen) ;
Ghia, Paolo (Universita Vita e Salute San Raffaele) ;
Gökbuget, N. (Department of Hematology/Oncology. Goethe University) ;
González-Calle, Verónica (Instituto de Investigación Biomédica de Salamanca) ;
Huntly, B. (Cambridge Stem Cell Institute. Department of Haematology. University of Cambridge) ;
Jäger, U. (Department of Medicine i. Clinical Division of Hematology and Hemostaseology. Medical University of Vienna) ;
Latino, N. J. (Head Office. European Society for Medical Oncology) ;
Douillard, Jean-Yves (Head Office. European Society for Medical Oncology) ;
Malcovati, Luca (Department of Hematology Oncology. Fondazione IRCCS Policlinico San Matteo) ;
Mateos, M. V. (Instituto de Investigación Biomédica de Salamanca) ;
Ossenkoppele, G. J. (Amsterdam Universitair Medische Centra (Amsterdam, Països Baixos)) ;
Porkka, K. (Helsinki University Hospital (Finlàndia)) ;
Raderer, M. (Department of Medicine i. Clinical Division of Oncology. Medical University of Vienna) ;
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Scarfò, Lydia (Universita Vita e Salute San Raffaele) ;
Wester, R. (Erasmus MC Cancer Institute (Rotterdam, Països Baixos)) ;
Zygoura, P. (Frontier Science Foundation-Hellas) ;
Sonneveld, P. (Department of Radiation Oncology. Erasmus MC Cancer Institute) ;
Universitat Autònoma de Barcelona
Objective Value frameworks in oncology have not been validated for the assessment of treatments in haematological malignancies, but to avoid overlaps and duplications it appears reasonable to build up experience on existing value frameworks, such as the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS). [...]
2020 - 10.1136/esmoopen-2019-000611
ESMO open, Vol. 5 Núm. 1 (20 2020) , p. e000611
|
|
|
5.
|
|
13 p, 2.7 MB |
Minimal residual disease level predicts outcome in adults with Ph-negative Bprecursor acute lymphoblastic leukemia
/
Gökbuget, Nicola (University Hospital of Frankfurt (Alemanya)) ;
Dombret, Hervé (Hôpital Saint-Louis, Université Paris Diderot) ;
Giebel, Sebastian (Maria Sklodowska Curie Memorial Cancer Center, Gliwice) ;
Bruggemann, Monika (Universitätsklinikum Schleswig-Holstein (Alemanya)) ;
Doubek, Michael (University Hospital Brno (República Txeca)) ;
Foà, Robin (Sapienza University of Rome) ;
Hoelzer, Dieter (University Hospital of Frankfurt (Alemanya)) ;
Kim, Christopher (Amgen Inc, Thousand Oaks, CA, USA) ;
Martinelli, Giovanni (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS) ;
Parovichnikova, Elena (National Research Center for Hematology, Moscow) ;
Rambaldi, Alessandro (Dipartimento di Oncologia ed Ematologia, Università degli Studi di Milano and Ospedale Papa Giovanni XXIII) ;
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Schoonen, Marieke (Amgen Ltd, London) ;
Stieglmaier, Julia M. (Amgen GmBH, Munich) ;
Zugmaier, Gerhard (Amgen GmBH, Munich) ;
Bassan, Renato (Ospedale dell'Angelo, Mestre-Venezia) ;
Universitat Autònoma de Barcelona
Objectives: Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. This study evaluated outcomes of patients with B-cell precursor ALL with MRD of ≥10−4. [...]
2019 - 10.1080/16078454.2019.1567654
Hematology, Vol. 24 Núm. 1 (2019) , p. 337-348
|
|
|
6.
|
|
7 p, 444.1 KB |
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia
/
Gökbuget, N. (Goethe University. University Hospital Frankfurt) ;
Kelsh, M. (Amgen (Thousand Oaks, Estats Units d'Amèrica)) ;
Chia, V. (Amgen (Thousand Oaks, Estats Units d'Amèrica)) ;
Advani, Anjali (Cleveland Clinic (Estats Units d'Amèrica)) ;
Bassan, Renato (Ospedale dell'Angelo (Venècia, Itàlia)) ;
Dombret, Hervé (Hôpital Saint-Louis (Paris, França)) ;
Doubek, Michael (University Hospital Brno (República Txeca)) ;
Fielding, A. K. (UCL Cancer Institute (Londres, Regne Unit)) ;
Giebel, S. (Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology (Polònia)) ;
Haddad, V. (Amgen Ltd. (Uxbridge, Regne Unit)) ;
Hoelzer, Dieter (Goethe University. University Hospital Frankfurt) ;
Holland, C. (Amgen Ltd. (Rockville, Estats Units d'Amèrica)) ;
Ifrah, N. (Centre Hospitalier Universitaire (Angers, França)) ;
Katz, A. (Amgen (Thousand Oaks, Estats Units d'Amèrica)) ;
Maniar, T. (Amgen (Thousand Oaks, Estats Units d'Amèrica)) ;
Martinelli, Giovanni (Policlinico Sant'Orsola-Malpighi (Bolònia, Itàlia)) ;
Morgades, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
O'Brien, Susan (University of Texas MD Anderson Cancer Center (Houston, Texas)) ;
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rowe, J. M. (Rambam Medical Center) ;
Stein, Anthony (City of Hope National Medical Center (Duarte, Estats Units d'Amèrica)) ;
Topp, M. (Universitätsklinikum Würzburg (Alemanya)) ;
Wadleigh, M. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Kantarjian, H. (University of Texas MD Anderson Cancer Center (Houston, Texas))
We compared outcomes from a single-arm study of blinatumomab in adult patients with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia (R/R ALL) with a historical data set from Europe and the United States. [...]
2016 - 10.1038/bcj.2016.84
Blood Cancer Journal, Vol. 6, Núm. 9 (September 2016) , p. e473
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
